Literature DB >> 35528467

Comparison of perioperative complications for extended vs standard pelvic lymph node dissection in patients undergoing radical prostatectomy for prostate cancer: a meta-analysis.

Jerry Kong1, Benjamin Lichtbroun1,2, Joshua Sterling3, Yaqun Wang4, Qingyang Wang5, Eric A Singer1,2, Thomas L Jang1,2, Saum Ghodoussipour1,2, Isaac Yi Kim6.   

Abstract

INTRODUCTION: Pelvic lymph node dissection (PLND) is widely performed for staging in men undergoing radical prostatectomy (RP) for prostate cancer. Our goal was to synthesize all available evidence and data to evaluate perioperative complications for two templates of PLND, standard (sPLND) vs extended (ePLND), at the time of RP in patients with prostate cancer.
METHODS: A meta-analysis was performed on relevant literature about complications during PLND. Pubmed, Scopus, WebofScience, and Cochrane Library were systematically searched through July 2021. Meta-analysis was conducted with both fixed-effects and random-effects models to estimate risk ratios (RRs) between treatments. A subgroup analysis was also conducted based on surgery type - open vs robotic.
RESULTS: 13 (1 randomized clinical trial and 12 observational studies) studies published between 1997 and 2019 with a total of 7,036 patients were analyzed. Pooled data showed complications in a random-effects model was lower in the sPLND group than the ePLND group (RR, 0.62; 95% CI 0.40-0.97). In a subgroup analysis, neither the open surgery subgroup nor the robotic surgery subgroup showed significant differences in complication rate between sPLND and ePLND.
CONCLUSION: ePLND is associated with a significantly greater risk of perioperative complication compared to sPLND, but not when comparing these templates performed via a robotic approach. Additional studies comparing the complication rates of sPLND and ePLND when utilizing a robotic approach should be conducted. AJCEU
Copyright © 2022.

Entities:  

Keywords:  Prostate cancer; complications; extended pelvic lymph node dissection; pelvic lymph node dissection; pelvic lymphadenectomy; radical prostatectomy

Year:  2022        PMID: 35528467      PMCID: PMC9077149     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  26 in total

Review 1.  A systematic review and meta-analysis of comparative studies on the efficacy of extended pelvic lymph node dissection in patients with clinically localized prostatic carcinoma.

Authors:  Liang Gao; Lu Yang; Xiao Lv; Siyuan Bu; Fan Wan; Shengqiang Qian; Qiang Wei; Ping Han; Tianyong Fan
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-27       Impact factor: 4.553

2.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

3.  The importance of pelvic lymph node dissection in men with clinically localized prostate cancer.

Authors:  Mohamad E Allaf; Alan W Partin; H Ballentine Carter
Journal:  Rev Urol       Date:  2006

4.  Extended pelvic lymph-node dissection is independently associated with improved overall survival in patients with prostate cancer at high-risk of lymph-node invasion.

Authors:  Akshay Sood; Jacob Keeley; Isaac Palma-Zamora; Deepansh Dalela; Sohrab Arora; James O Peabody; Craig G Rogers; Francesco Montorsi; Mani Menon; Alberto Briganti; Firas Abdollah
Journal:  BJU Int       Date:  2020-03-03       Impact factor: 5.588

5.  Extending the indications and anatomical limits of pelvic lymph node dissection for prostate cancer: improved staging or increased morbidity?

Authors:  Karim Touijer; Rodrigo Pinochet Fuenzalida; Farhang Rabbani; Philippe Paparel; Lucas Nogueira; Angel M Cronin; Samson W Fine; Bertrand Guillonneau
Journal:  BJU Int       Date:  2010-12-24       Impact factor: 5.588

6.  Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.

Authors:  Muammer Altok; Kara Babaian; Mary F Achim; Grace C Achim; Patricia Troncoso; Surena F Matin; Brian F Chapin; John W Davis
Journal:  BJU Int       Date:  2018-03-25       Impact factor: 5.588

7.  [Comparison of the morbidity between limited and extended pelvic lymphadenectomy during laparoscopic radical prostatectomy].

Authors:  B Rousseau; L Doucet; M-A Perrouin Verbe; G Papin; A Erauso; V Joulin; C Deruelle; A Valeri; G Fournier
Journal:  Prog Urol       Date:  2013-11-05       Impact factor: 0.915

Review 8.  The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.

Authors:  Nicola Fossati; Peter-Paul M Willemse; Thomas Van den Broeck; Roderick C N van den Bergh; Cathy Yuhong Yuan; Erik Briers; Joaquim Bellmunt; Michel Bolla; Philip Cornford; Maria De Santis; Ekelechi MacPepple; Ann M Henry; Malcolm D Mason; Vsevolod B Matveev; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Thomas B Lam; Nicolas Mottet; Steven Joniau
Journal:  Eur Urol       Date:  2017-01-24       Impact factor: 20.096

Review 9.  Pelvic lymph node dissection in prostate cancer.

Authors:  Alberto Briganti; Michael L Blute; James H Eastham; Markus Graefen; Axel Heidenreich; Jeffrey R Karnes; Francesco Montorsi; Urs E Studer
Journal:  Eur Urol       Date:  2009-03-10       Impact factor: 20.096

10.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.

Authors:  Martin G Sanda; Jeffrey A Cadeddu; Erin Kirkby; Ronald C Chen; Tony Crispino; Joann Fontanarosa; Stephen J Freedland; Kirsten Greene; Laurence H Klotz; Danil V Makarov; Joel B Nelson; George Rodrigues; Howard M Sandler; Mary Ellen Taplin; Jonathan R Treadwell
Journal:  J Urol       Date:  2018-01-10       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.